Karyopharm Therapeut (KPTI) Stock Price, Quote & News

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 658 0600

Website: www.karyopharm.com

Address:

85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States

celebratelife Oct. 23 at 8:29 PM

$KPTI Board's biggest mistake but it's not too late: https://x.com/karyowatch/status/1981457748350161050

0 · Reply

celebratelife Oct. 23 at 4:32 PM

$KPTI CEO Richard Paulson buying celeb status using our money. His evil destruction of our assets is unforgivable. https://x.com/karyowatch/status/1981393735259930681

0 · Reply

celebratelife Oct. 22 at 9:28 PM

$KPTI Dr. DD: https://x.com/karyowatch/status/1981090655892812096

0 · Reply

jdlman Oct. 22 at 4:15 PM

$KPTI what the heck happed hee in the last hour

0 · Reply

Argentum99 Oct. 22 at 12:08 PM

$KPTI

0 · Reply

Argentum99 Oct. 22 at 12:06 PM

$KPTI

0 · Reply

celebratelife Oct. 21 at 10:46 PM

$KPTI Emailed this: https://x.com/karyowatch/status/1980767314384650644 to the lousy Board: [email protected], [email protected], [email protected], [email protected], [email protected], [email protected], [email protected] I exclude Paulson since he IS the main problem.

0 · Reply

nacho217 Oct. 21 at 6:40 PM

$KPTI from 8.4m shares to 15.6m, this what they do best, hope you got back all pain to made to shareholders, mf**

1 · Reply

nacho217 Oct. 21 at 6:36 PM

$KPTI this mgm really deserves the worst, just a bloody gang of gangters

0 · Reply

Tumble51 Oct. 21 at 10:47 AM

$ACAD $BIVI $CUE $INMB $KPTI kryptonite here is Choung !!! The CEO

0 · Reply

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Oct 8, 2025, 7:00 AM EDT - 17 days ago

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Oct 1, 2025, 4:05 PM EDT - 24 days ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 7:00 AM EDT - 6 weeks ago

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Aug 11, 2025, 11:02 AM EDT - 2 months ago

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 7:30 AM EDT - 2 months ago

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Jun 3, 2025, 8:00 AM EDT - 5 months ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 5 months ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:31 AM EDT - 5 months ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 13, 2025, 1:39 PM EDT - 5 months ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 13, 2025, 7:15 AM EDT - 5 months ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 5 months ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 8, 2025, 4:05 PM EDT - 6 months ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Mar 5, 2025, 12:00 AM EST - 8 months ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Feb 24, 2025, 8:40 AM EST - 8 months ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 19, 2025, 11:05 AM EST - 8 months ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:30 AM EST - 8 months ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 13, 2025, 4:30 AM EST - 9 months ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 12, 2025, 7:00 AM EST - 9 months ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Jan 13, 2025, 8:30 AM EST - 10 months ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 2, 2025, 7:00 AM EST - 10 months ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Dec 9, 2024, 8:00 AM EST - 11 months ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 3, 2024, 7:00 AM EST - 11 months ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Nov 25, 2024, 7:00 AM EST - 11 months ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:05 PM EST - 1 year ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:22 PM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:30 PM EST - 1 year ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 17, 2024, 10:35 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Sep 23, 2024, 5:00 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Karyopharm to Participate at Upcoming Investor Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 1, 2024, 1:45 PM EDT - 1 year ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

May 29, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 3:38 PM EDT - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 2, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 30, 2024, 2:28 PM EDT - 1 year ago

Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

celebratelife Oct. 23 at 8:29 PM

$KPTI Board's biggest mistake but it's not too late: https://x.com/karyowatch/status/1981457748350161050

0 · Reply

celebratelife Oct. 23 at 4:32 PM

$KPTI CEO Richard Paulson buying celeb status using our money. His evil destruction of our assets is unforgivable. https://x.com/karyowatch/status/1981393735259930681

0 · Reply

celebratelife Oct. 22 at 9:28 PM

$KPTI Dr. DD: https://x.com/karyowatch/status/1981090655892812096

0 · Reply

jdlman Oct. 22 at 4:15 PM

$KPTI what the heck happed hee in the last hour

0 · Reply

Argentum99 Oct. 22 at 12:08 PM

$KPTI

0 · Reply

Argentum99 Oct. 22 at 12:06 PM

$KPTI

0 · Reply

celebratelife Oct. 21 at 10:46 PM

0 · Reply

nacho217 Oct. 21 at 6:40 PM

$KPTI from 8.4m shares to 15.6m, this what they do best, hope you got back all pain to made to shareholders, mf**

1 · Reply

nacho217 Oct. 21 at 6:36 PM

$KPTI this mgm really deserves the worst, just a bloody gang of gangters

0 · Reply

Tumble51 Oct. 21 at 10:47 AM

$ACAD $BIVI $CUE $INMB $KPTI kryptonite here is Choung !!! The CEO

0 · Reply

celebratelife Oct. 21 at 4:11 AM

$KPTI Last hour: 100k shares = 1.5mm pre-RSS

0 · Reply

celebratelife Oct. 20 at 7:55 PM

$KPTI

0 · Reply

Twills08 Oct. 20 at 4:01 AM

$KPTI watching...

0 · Reply

celebratelife Oct. 19 at 8:33 PM

$KPTI Instead of firing Richard Paulson he's been compensated over $25 million https://x.com/karyowatch/status/1980009308319560066

0 · Reply

JFais Oct. 18 at 3:01 PM

$XBI $IBB Weekly Recap is out https://seekingalpha.com/mp/1243-roty-biotech-community/articles/6213624-weekly-recap-october-11th-to-16th?source=tweet As goes the trend, it's pretty packed so I tried to focus on most relevant discussions including: -New member with $1M position in $SMMT asks about risk mgmt into data (group helped him make an optimal decision) -Q3 DCA portfolio update (process of steadily growing a small portfolio) -Started a ROTY Member Directory (much requested feature to better decide who in Chat you wish to follow in Chat) -Pushback on my most recent commercial-stage entries (I like it when people tear into my ideas & thesis) -Discussion on portfolio hedges, possible turnaround in $KPTI, $CELC data & multiple veteran members posting their updated portfolios

0 · Reply

celebratelife Oct. 18 at 2:13 PM

$KPTI DR.DD'S WARNING IGNORED BY VALUE DESTROYERS PAULSON & GREENE https://x.com/karyowatch/status/1979551190443807058

0 · Reply

celebratelife Oct. 18 at 2:10 PM

$KPTI ANOTHER INVESTOR WARNING THAT WAS IGNORED BY PAULSON, GREENE. https://x.com/karyowatch/status/1979550529572450659

0 · Reply

celebratelife Oct. 17 at 10:54 PM

$KPTI Silverman new 10% owner https://x.com/karyowatch/status/1979319614967325110

0 · Reply

celebratelife Oct. 17 at 7:03 PM

$KPTI

1 · Reply

celebratelife Oct. 17 at 3:25 PM

$KPTI The Case For Firing CEO Richard Paulson Has Never Been Stronger https://x.com/karyowatch/status/1979206961926127743

0 · Reply

celebratelife Oct. 16 at 6:02 PM

$KPTI *UPDATED LINK* - Keeping Richard Paulson As CEO Is Very Risky & A Gift To Shorts https://x.com/karyowatch/status/1978883874068316534

0 · Reply

celebratelife Oct. 16 at 4:41 PM

$KPTI Keeping Richard Paulson As CEO Is Very Risky & A Gift To Shorts https://x.com/karyowatch/status/1978863836003225622

1 · Reply

Market Cap	53.68M
Revenue (ttm)	145.24M
Net Income (ttm)	-76.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52.62%
Debt to Equity Ratio	-0.50

Volume	84,500
Avg Vol	220,044
Day's Range	N/A - N/A
Shares Out	8.67M
Stochastic %K	67%
Beta	0.34
Analysts	Strong Sell
Price Target	$15.67